Loading
A phase 1/2 trial of SI-B001 in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 1/2 interventional study registered as NCT05668858 by Sichuan Baili Pharmaceutical Co., Ltd., with 70 participants enrolled, started 2023-02-10 and due to reach its primary completion in 2026-12. Interventions recorded: SI-B001 and SI-B003.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/